



# HEDIS Reporting Year 2022 (RY2022) Health Plan Accreditation (HPA) Administrative Reporting Measures

## Measuring Performance for Calendar Year 2021

**HEDIS® Administrative Measure:** *Data collected from claims submission, lab data, pharmacy data, vision service provider data, and other supplemental data sources*

**Health Plan Accreditation (HPA):** *Uses HEDIS data to effectively measure the health plan's care and service performance.*

*The following measures are applicable to Administrative Reporting only.*

| HEDIS Measure  | Measure Indicator   | Measure Description  |
|--|---|--|
| <b>W30</b><br>Well-Child Visits in the First 30 Months of Life | <ul style="list-style-type: none"> <li>• Well-Child Visits in the First 15 Months. Children who turned 15 months old during 2021: Six or more well-child visits.</li> <li>• Well-Child Visits for Age 15 Months-30 Months. Children who turned 30 months old during 2021: Two or more well-child visits.</li> </ul> | The percentage of members who had well-child visits with a PCP during the last 15 months.  |
| <b>WCV</b><br>Child and Adolescent Well-Care Visits            | <ul style="list-style-type: none"> <li>• 3-21 years of age as of December 31, 2021 with one or more well-care visits with a PCP or an OB/GYN practitioner, but the practitioner does not have to be the practitioner assigned to the member.</li> </ul>   | The percentage of members 3-21 years of age who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during 2021. |



# HEDIS Reporting Year 2022 (RY2022) Health Plan Accreditation (HPA) Administrative Reporting Measures

*The following measures are applicable to Administrative and Accreditation reporting:*

| HEDIS Measure                              | Measure Indicator   | Measure Description  |
|--|---|--|
| <b>BCS</b><br>Breast Cancer Screening      | <ul style="list-style-type: none"> <li>Women 50-74 years of age who had a mammogram to screen for breast cancer during the measurement period.</li> </ul> | The percentage of women 50-74 years of age who had one or more mammograms on or between October 1, 2019 and December 31, 2021                                    |
| <b>CHL</b><br>Chlamydia Screening in Women | <ul style="list-style-type: none"> <li>Women 16-24 years of age who had a claim or encounter indicating sexual activity during 2021.</li> </ul>           | Percentage of women 16-24 years of age, as of December 31, 2021, who were identified as sexually active and who had at least one test for chlamydia during 2021. |



# HEDIS Reporting Year 2022 (RY2022) Health Plan Accreditation (HPA) Administrative Reporting Measures

*The following measures are applicable to Health Plan Accreditation reporting:*

| HEDIS Measure                              | Measure Indicator/Stratifications  | Measure Description  |
|--|--|--|
| <b>AMR:</b><br>Asthma Medication Ratio     | <ul style="list-style-type: none"> <li>Members 5-64 years of age who had a claim and/or encounter for persistent asthma during 2020 and 2021.</li> </ul>   | The percentage of members ages 5-64 years with persistent asthma who have a ratio of controller to total asthma medications of 0.50 or greater during 2021.  |
| <b>FVA:</b><br>Flu Vaccinations for Adults | <ul style="list-style-type: none"> <li>Members 18-64 years as of July 1, 2021.</li> </ul>  | The percentage of Medicaid members 18-64 years of age who received a flu vaccination between July 1 of the measurement year (2021) and the date when the CAHPS 5.0H survey was completed.          |
| <b>PRS:</b><br>Prenatal Immunizations      | <ul style="list-style-type: none"> <li>Deliveries where members received adult influenza vaccine and/or an Tdap vaccine on or between July 1 of the year prior (2020) to the Measurement Period and the delivery date; <i>or</i></li> <li>Deliveries where members had an influenza virus vaccine and/or Tdap vaccine adverse reaction anytime during or before the Measurement Period.</li> </ul> | The percentage of deliveries in the Measurement Period (January 1-December 31) in which women had received influenza and tetanus, diphtheria toxoids and acellular pertussis (T-dap) vaccinations. |



# HEDIS Reporting Year 2022 (RY2022)

## Health Plan Accreditation (HPA)

### Administrative Reporting Measures

| HEDIS Measure  | Measure Indicator/Stratifications  | Measure Description  |
|--|--|--|
| <p><b>SPD:</b></p> <ul style="list-style-type: none"> <li>Statin Therapy for Patients with Diabetes—Received Statin Therapy</li> <li>Statin Therapy for Patients with Diabetes—Statin Adherence 80%</li> </ul>                                   | <ul style="list-style-type: none"> <li>Members 40-75 years as of December 31, 2021 who had a claim/encounter data and/or pharmacy data (related to diabetes) with a diabetes diagnosis.</li> </ul>   | <p>The percentage of member 40-75 years of age during the measurement year (2021) with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) who met the following criteria.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> <li><i>Received Statin Therapy.</i> Members who were dispensed at least one statin medication of any intensity during the measurement year.</li> <li><i>Statin Adherence 80%.</i> Members who remained on a statin medication of any intensity for at least 80% of the treatment period.</li> </ol>  |
| <p><b>SPC:</b></p> <ul style="list-style-type: none"> <li>Statin Therapy for Patients with Cardiovascular Disease—Received Statin Therapy</li> <li>Statin Therapy for Patients with Cardiovascular Disease—Statin Adherence 80%—Total</li> </ul> | <p>Report two age/gender stratifications and a total rate:</p> <ul style="list-style-type: none"> <li>Males 21-75 years as of December 31 of the measurement year</li> <li>Females 40-75 years as of December 31 of the measurement year</li> <li>Total</li> </ul> | <p>The percentage of males 21-75 years of age and females 40-75 years of age during the measurement year (2021), who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria.</p> <p>The following rates are reported:</p> <ol style="list-style-type: none"> <li><i>Received Statin Therapy.</i> Members who were dispensed at least one high-intensity or moderate-intensity statin medication during the measurement year.</li> <li><i>Statin Adherence 80%.</i> Members who remained on a high-intensity or moderate-intensity statin medication for at least 80% of the treatment period.</li> </ol> |



# HEDIS Reporting Year 2022 (RY2022) Health Plan Accreditation (HPA) Administrative Reporting Measures

| HEDIS Measure   | Measure Indicator/Stratifications   | Measure Description   |
|---|---|---|
| <p><b>MSC:</b><br/>           Medical Assistance with Smoking and Tobacco Use Cessation</p> | <p>Medical Assistance with Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit</p> <ul style="list-style-type: none"> <li>Members 18 years and older as of December 31, 2021.</li> </ul> | <p>The following components of this measure assess different facets of providing medical assistance with smoking and tobacco use cessation:</p> <p><b>Advising Smokers and Tobacco Users to Quit</b></p> <p>A rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who received advice to quit during the measurement year.</p> <p><b>Discussing Cessation Medications</b></p> <p>A rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who discussed or were recommended cessation medications during measurement year.</p> <p><b>Discussing Cessation Strategies</b></p> <p>A rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who discussed or were provided cessation methods or strategies during the measurement year.</p> |



# HEDIS Reporting Year 2022 (RY2022)

## Health Plan Accreditation (HPA)

### Administrative Reporting Measures

| HEDIS Measure  | Measure Indicator/Stratifications  | Measure Description  |
|--|--|--|
| <b>AMM:</b><br>Antidepressant Medication Management                      | <ul style="list-style-type: none"> <li>• 18 years and older as of April 30 of the measurement year (2021)</li> </ul>   | Percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication treatment.<br><br>Two rates are reported: <ol style="list-style-type: none"> <li>1. <i>Effective Acute Phase Treatment.</i> The percentage of members who remained on an antidepressant medication for at least 84 days (12 weeks).</li> <li>2. <i>Effective Continuation Phase Treatment.</i> The percentage of members who remained on an antidepressant medication for at least 180 days (6 months).</li> </ol> |
| <b>FUH:</b><br>Follow-up After Hospitalization for Mental Illness—7 days | An acute inpatient discharge with a principal diagnosis of mental illness or intentional self-harm on the discharge claim on or between January 1 and December 1 of the measurement year; 6 years and older as of the date of discharge. Report three age stratifications and total rate: <ul style="list-style-type: none"> <li>• 6-17 years</li> <li>• 18-64 years</li> <li>• 65 years and older</li> <li>• Total</li> </ul> | The percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit with a mental health provider.<br><br>Two rates are reported: <ol style="list-style-type: none"> <li>1. The percentage of discharges for which the member received follow-up within 30 days after discharge.</li> <li>2. The percentage of discharges for which the member received follow-up within 7 days after discharge.</li> </ol>  |



# HEDIS Reporting Year 2022 (RY2022) Health Plan Accreditation (HPA) Administrative Reporting Measures

| HEDIS Measure   | Measure Indicator/Stratifications   | Measure Description  |
|---|---|--|
| <b>FUM:</b><br>Follow-up After Emergency Department Visit for Mental Illness—7 days—Total                             | A follow-up visit with any practitioner, with a principal diagnosis of a mental health disorder or with a principal diagnosis of intentional self-harm and any diagnosis of a mental health disorder within 7 days after the ED visit (8 total days). Include visits that occur on the date of the ED visit; 6 years and older as of the date of the ED visit. Report three age stratifications: <ul style="list-style-type: none"> <li>• 6-17 years</li> <li>• 18-64 years</li> <li>• 65 years and older</li> <li>• Total</li> </ul> | The percentage of emergency department (ED) visits for members 6 years of age and older with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for mental illness.<br><br>Two rates are reported: <ol style="list-style-type: none"> <li>1. The percentage of ED visits for which the member received follow-up within 7 days of the ED visit (8 total days).</li> </ol> |
| <b>FUA:</b><br>Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence—7 days—Total | Members 13 years and older as of the ED visit on or between January 1 and December 1, 2021. Report two age stratifications and a total rate: <ul style="list-style-type: none"> <li>• 13-17 years</li> <li>• 18 and older</li> <li>• Total</li> </ul>   | The percentage of emergency department (ED) visits for members 13 years of age and older with a principal diagnosis of alcohol or other drug (AOD) abuse or dependence, who had a follow-up visit for AOD.<br><br>Rate reported for HPA: <ol style="list-style-type: none"> <li>1. The percentage of ED visits for which the member received follow-up within 7 days of the ED visit (8 total days).</li> </ol>    |



# HEDIS Reporting Year 2022 (RY2022)

## Health Plan Accreditation (HPA)

### Administrative Reporting Measures

| HEDIS Measure  | Measure Indicator/Stratifications  | Measure Description   |
|--|--|---|
| <b>FUI:</b><br>Follow-up After High-Intensity Care for Substance Use Disorder—7 days—Total   | Members 13 years and older as of the date of discharge, stay or event for a principal diagnosis of substance use disorder on or between January 1 and December 1, 2021. Report three age stratifications and total rate: <ul style="list-style-type: none"> <li>• 13-17 years</li> <li>• 18-64 years</li> <li>• 65 years and older</li> <li>• Total</li> </ul> | The percentage of acute inpatient hospitalizations, residential treatment or detoxification visits for a diagnosis of substance use disorder among members 13 years of age and older that result in a follow-up visit or service for substance use disorder.<br><br>Rate Reported for HPA: <ol style="list-style-type: none"> <li>1. The percentage of visits or discharges for which the member received follow-up for substance use disorder within the 7 days after the visit or discharge.</li> </ol>   |
| <b>IET:</b><br>Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment—<br>Engagement of AOD Treatment—<br>Total | Members 13 years and older as of December 31, 2021. Report two age stratifications and a total rate: <ul style="list-style-type: none"> <li>• 13-17 years</li> <li>• 18+ years</li> <li>• Total</li> </ul>   | The percentage of adolescent and adult members with a new episode of other drug (AOD) abuse or dependence who receive the following: <ul style="list-style-type: none"> <li>• <i>Initiation of AOD Treatment.</i> The percentage of members who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth or medication treatment within 14 days of the diagnosis.</li> <li>• <i>Engagement of AOD Treatment.</i> The percentage of members who initiated treatment and who were engaged in ongoing AOD treatment within 34 days of the initiation visit.</li> </ul> |



# HEDIS Reporting Year 2022 (RY2022)

## Health Plan Accreditation (HPA)

### Administrative Reporting Measures

| HEDIS Measure   | Measure Indicator/Stratifications  | Measure Description  |
|---|--|--|
| <b>ADD:</b><br>Follow-up Care for Children Prescribed ADHD Medication—Continuation & Maintenance Phase                      | <ul style="list-style-type: none"> <li>6 years of age as of March 1 of the year prior to the measurement year to 12 years as of the last calendar day in February of the measurement year.</li> <li>120 days (4 months) prior to the IPSD (Index Prescription Star Date) through 30 days after the IPSD</li> </ul> | The percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication dispensed.<br><br>Two rates are reported: <ol style="list-style-type: none"> <li><i>Initiation Phase.</i> The percentage of members 6-12 years of age with an ambulatory prescription dispensed for ADHD medication, who had one follow-up visit with a practitioner with prescribing authority during the 30-day Initiation Phase.</li> <li><i>Continuation and Maintenance (C&amp;M) Phase.</i> The percentage of members 6-12 years of age with an ambulatory prescription dispensed for ADHD medication, who remained on the medication at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.</li> </ol> |
| <b>SSD:</b><br>Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications | <ul style="list-style-type: none"> <li>18-64 years old as of December 31, 2021</li> <li>A glucose test or an HbA1c test performed during the measurement year (2021)</li> </ul>  | The percentage of members 18-64 years of age with schizophrenia, schizoaffective disorder or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.   |
| <b>SAA:</b><br>Adherence to antipsychotic medications for individuals with schizophrenia                                    | <ul style="list-style-type: none"> <li>18 years of age and older as of January 1, 2021 who had claim/encounter data and/or pharmacy data (related to antipsychotic medications) with a schizophrenia diagnosis.</li> </ul>   | The percentage of members 18 years of age and older during the measurement year with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.  |



# HEDIS Reporting Year 2022 (RY2022)

## Health Plan Accreditation (HPA)

### Administrative Reporting Measures

| HEDIS Measure  | Measure Indicator/Stratifications   | Measure Description  |
|--|---|--|
| <b>APM:</b><br>Metabolic Monitoring for Children and Adolescents on Antipsychotics—Blood Glucose and Cholesterol Testing—Total | Members 1-17 years as of December 31, 2021. Report two age stratifications and a total rate for each of the three indicators: <ul style="list-style-type: none"> <li>• 1-11 years</li> <li>• 12-17 years</li> <li>• Total</li> </ul>  | The percentage of children and adolescents 1-17 years of age who had two or more antipsychotic prescriptions and had metabolic testing.<br><br>Three rates are reported: <ol style="list-style-type: none"> <li>1. The percentage of children and adolescents on antipsychotics who received blood glucose testing.</li> <li>2. The percentage of children and adolescents on antipsychotics who received cholesterol testing.</li> <li>3. The percentage of children and adolescents on antipsychotics who received blood glucose and cholesterol testing.</li> </ol> |
| <b>APP:</b><br>First-line psychosocial care for youth on antipsychotic medications   | Members 1-17 years as of December 31, 2021 who had documentation of psychosocial care in the 121-day period from 90 days prior to the IPSD (Index Prescription Start Date) through 30 days after the IPSD. Report two age stratifications and a total rate: <ul style="list-style-type: none"> <li>• 1-11 years</li> <li>• 12-17 years</li> <li>• Total</li> </ul> The total is the sum of the age stratifications. | The percentage of children and adolescents 1-17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment.  |
| <b>PCR:</b><br>Plan All-Cause Readmissions   | An acute inpatient or observation stay discharge on or between January 1 and December 1, 2021 for ages 18-64 years.   | For members 18 years of age and older, the number of acute inpatient and observation stays during the measurement year that were followed by an unplanned acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission.  |



# HEDIS Reporting Year 2022 (RY2022)

## Health Plan Accreditation (HPA)

### Administrative Reporting Measures

| HEDIS Measure  | Measure Indicator/Stratifications  | Measure Description  |
|--|--|--|
| <b>AAB:</b><br>Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis— Total | Members who were 3 months or older as of the Episode Date – the date of service for outpatient, telephone, observation or ED visit or virtual check-in – between July 1, 2020 through June 30, 2021 with a diagnosis of acute bronchitis/bronchiolitis.  | The Percentage of episodes for members ages 3 months and older with a diagnosis of acute bronchitis/bronchiolitis that did not result in an antibiotic dispensing event.                             |
| <b>CWP:</b><br>Appropriate Testing for Pharyngitis   | Members who were 3 months or older who had a group A streptococcus test in the seven-day period from three days prior to the Episode Date through three days after the Episode Date - the date of service for outpatient, telephone, observation or ED visit or virtual check-in – between July 1, 2020 through June 30, 2021 with a diagnosis of pharyngitis. | The percentage of episodes for members 3 years and older where the member was diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode. |
| <b>LBP:</b><br>Use of Imaging Studies for Low Back Pain                                    | 18 years of age as of January 1, 2021 to 50 years of age as of December 31, 2021 who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.  | The percentage of members with a primary diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.                                   |



# HEDIS Reporting Year 2022 (RY2022)

## Health Plan Accreditation (HPA)

### Administrative Reporting Measures

| HEDIS Measure  | Measure Indicator/Stratifications  | Measure Description   |
|--|--|---|
| <b>URI:</b><br>Appropriate Treatment for Upper Respiratory Infection | Members who were 3 months of age or older as of the Episode Date who were dispensed a prescription for an antibiotic medication on or 3 days after the Episode Date.   | The percentage of episodes for members 3 months of age and older with a diagnosis of upper respiratory infection (URI) that did not result in an antibiotic dispensing event.   |
| <b>HDO:</b><br>Use of Opioids at High Dosage                         | Members 18 years and older as of January 1, 2021 whose average MME was $\geq 90$ during the treatment period - The treatment period start date is the start date of the earliest dispensing event during the measurement year. The treatment period end date is the last end date during the measurement year. | The proportion of members 18 years and older who received a prescription opioids at a high dosage (average morphine milligram equivalent dose [MME] $\geq 90$ ) for $\geq 15$ days during the measurement year (2021).<br><br><i>Note: A lower rate indicates better performance.</i> |



# HEDIS Reporting Year 2022 (RY2022)

## Health Plan Accreditation (HPA)

### Administrative Reporting Measures

| HEDIS Measure  | Measure Indicator/Stratifications   | Measure Description  |
|--|---|--|
| <p><b>UOP:</b><br/>Use of Opioids from Multiple Providers—Multiple Prescribers and Multiple Pharmacies</p> | <p>Members 18 years and older as of January 1, 2021.</p> <p style="text-align: center;"><i>See indicator details under measure description.</i></p>   | <p>The proportion of members 18 years and older, receiving prescription opioids for <math>\geq 15</math> days during the measurement year who received opioids from multiple providers.</p> <p>Three rates are reported:</p> <ol style="list-style-type: none"> <li>1. <i>Multiple Prescribers:</i> The proportion of members receiving prescriptions for opioids from four or more different prescribers during the measurement year.</li> <li>2. <i>Multiple Pharmacies:</i> The proportion of members receiving prescriptions for opioids from four or more different pharmacies during the measurement year.</li> <li>3. <i>Multiple Prescribers and Multiple Pharmacies:</i> The proportion of members receiving prescriptions for opioids from four or more different prescribers and four or more different pharmacies during the measurement year (i.e., the proportion of members who are numerator compliant for both the Multiple Prescribers and Multiple Pharmacies rates).</li> </ol> <p><i>Note: A lower rate indicates better performance for all three rates.</i></p> |
| <p><b>COU:</b><br/>Risk of Continued Opioid Use</p>  | <p>Members 18 years and older as of November 1 of the year prior to the measurement year (2021).</p> <p>Report two age stratifications and a total rate:</p> <ul style="list-style-type: none"> <li>• 18-64 years</li> <li>• 65 years and older</li> <li>• Total</li> </ul> | <p>The percentage of members 18 years of age and older who have a new episode of opioid use that puts them at risk of continued opioid use.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> <li>1. The percentage of members with at least 15 days of prescription opioids in a 30-day period.</li> <li>2. The percentage of members with at least 31 days of prescription opioids in a 62-day period.</li> </ol> <p><i>Note: A lower rate indicates better performance.</i></p>   |



# HEDIS Reporting Year 2022 (RY2022)

## Health Plan Accreditation (HPA)

### Administrative Reporting Measures

| HEDIS Measure  | Measure Indicator/Stratifications  | Measure Description  |
|--|--|--|
| <b>POD:</b><br>Pharmacotherapy for Opioid Use Disorder         | 16 years and older as of December 31, 2021 with new OUD pharmacotherapy events with OUD pharmacotherapy for 180 or more days without a gap in treatment of 8 or more consecutive days.   | The percentage of new opioid disorder (OUD) pharmacotherapy events with OUD pharmacotherapy for 180 or more days among members age 16 and older with a diagnosis of OUD.   |
| <b>PCE:</b><br>Pharmacotherapy Management of COPD Exacerbation | <ul style="list-style-type: none"> <li>• Pharmacotherapy Management of COPD Exacerbation—Systemic Corticosteroid</li> <li>• Pharmacotherapy Management of COPD Exacerbation—Bronchodilator</li> </ul> <p><i>See indicator details under measure description.</i></p> | The percentage of COPD exacerbations for members 40 years of age and older who had an acute inpatient discharge or ED visit on or between January 1 – November 30 of the measurement year and who were dispensed appropriate medications.<br><br>Two rates are reported: <ol style="list-style-type: none"> <li>1. Dispensed a systemic corticosteroid (or there was evidence of an active prescription) with 14 days of the event.</li> <li>2. Dispensed a bronchodilator (or there was evidence of an active prescription) within 30 days of the event.</li> </ol> |

“HEDIS® is a registered trademark of the National Committee on Quality Assurance (NCQA)”